AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

In a small, single-arm study, 16 breast cancer survivors with cognitive impairment had improved perceived cognitive-function scores after taking oxaloacetate for eight weeks. The findings are preliminary: there was no control group, and a randomized placebo-controlled study is expected to begin enrolling before the end of 2026.

A small study of oxaloacetate found improved perceived cognitive function after eight weeks of treatment in 16 breast cancer survivors with cancer-related cognitive impairment, according to results reported October 23. The uncontrolled study cannot show whether the supplement caused the gains, but its findings are informing plans for a randomized, placebo-controlled trial.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The 18 participants took 500 milligrams of oxaloacetate twice daily for eight weeks; 16 completed the study and were included in the reported results. All 16 had statistically significant and clinically meaningful improvement on the FACT-Cog PCI, a measure of perceived cognitive impairment. The group’s mean score rose from 29.1 at baseline to 55.5 at eight weeks, which the investigators said moved the average from the impaired range into the normal range. Improvement was apparent at four weeks and generally increased over the following month.

Testing also indicated improvement in executive function and processing speed. Participants reported gains in fatigue and physical functioning, while insomnia showed a trend toward improvement. The treatment was described as generally well tolerated apart from gastrointestinal symptoms, including indigestion, bloating, constipation and diarrhea. The report does not establish how long any improvement lasts after treatment stops.

The study was led by Patricia Ganz, MD, of UCLA Health and published in JCO Oncology Advances, according to the supplied report. The investigators initially set a two-step design, with a four-point improvement in FACT-Cog PCI among the first nine participants defined as a positive result. The preliminary analysis found a 27-point improvement in that group. The authors said those early changes led them to redesign the study to finish with fewer participants and move more quickly toward a controlled trial.

At a glance
reportWhen: Study report published October 23, 2026…
The developmentA preliminary study reported improved cognitive-function scores among breast cancer survivors who took oxaloacetate for eight weeks, prompting plans for a placebo-controlled trial.

A Possible New Approach to Cancer Brain Fog

Cancer-related cognitive impairment can affect memory, concentration and other mental functions after treatment, and may interfere with everyday activities. Often called “chemo brain” or “brain fog,” it is reported among cancer survivors and is particularly well studied in people treated for breast cancer. The results offer a signal worth testing because participants’ scores improved across the study, while medication options for the condition are limited.

The study also examined a supplement rather than the behavioral approaches that have featured in much prior research, including exercise and support for anxiety, depression and related symptoms. That does not show oxaloacetate is more effective, easier to use or suitable for patients generally. If a larger controlled study confirms benefit and clarifies safety, the supplement could merit consideration as one part of care. For now, patients should not treat these results as proof of effectiveness or change their care based on the preliminary findings.

Products Worth Considering

Garmin Forerunner 265 GPS Running Smartwatch, 46 mm, Black/Powder Gray

Garmin Forerunner 265 GPS Running Smartwatch, 46 mm, Black/Powder Gray

As an affiliate, we earn on qualifying purchases.

Why Researchers Tested Oxaloacetate

Oxaloacetate is a naturally occurring human metabolite involved in cellular energy production and in regulation of glutamate, a neurotransmitter connected to cognitive function. Researchers cited this biological role, earlier studies of oxaloacetate for cognition and fatigue, and the limited number of drug-based approaches for cancer-related impairment as reasons to study it in breast cancer survivors. The supplied report also describes a small randomized study in people with long COVID that found improved cognitive performance, but that population and condition differ from the cancer-survivor group.

The study enrolled patients who were one to five years past cancer treatment and had a PROMIS questionnaire score below 12, which the report characterizes as moderately severe impairment. Cognitive symptoms can occur in people with cancers other than breast cancer, but this trial included breast cancer survivors. The causes of cancer-related cognitive impairment are not fully understood. Some chemotherapy drugs can cross the blood-brain barrier and have recognized neurotoxic effects, though the study does not establish a single cause for participants’ symptoms.

“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”

— Patricia Ganz, MD, UCLA Health, in a press release

What the Small Trial Cannot Show

The study had no placebo or comparison group, and only 16 participants completed it. Without a control group, researchers cannot determine how much of the change came from oxaloacetate rather than factors such as expectations, natural variation or other influences. The results also do not establish whether the supplement works for people with other cancers, how it compares with existing supportive approaches, or whether benefits persist after eight weeks.

The report says gastrointestinal effects were the most commonly reported adverse events, but it does not provide a full breakdown of their frequency or severity in the supplied material. Longer-term safety, the best treatment duration and whether particular patients are more likely to benefit remain unknown. The reported movement in the group average into the normal range is not evidence that every participant’s impairment resolved or that the supplement is an established treatment.

A Placebo-Controlled Trial Is Planned

A randomized, placebo-controlled phase II study of oxaloacetate for cancer-related cognitive impairment is expected to begin enrollment before the end of 2026, according to the report. The next study should help determine whether improvements exceed those seen with placebo and provide stronger evidence about the supplement’s effects and tolerability. The available material does not specify the planned enrollment, trial sites, duration or exact start date.

Until controlled results are available, oxaloacetate remains an investigational approach for this condition, not a proven treatment. People experiencing cognitive changes after cancer treatment can discuss symptoms and available supportive care with their oncology team. Anyone considering a supplement should also review it with a qualified clinician, particularly while receiving cancer treatment or taking other medicines.

Key Questions

What did the oxaloacetate study find?

In this small, uncontrolled study, all 16 participants who completed eight weeks had improved scores on a measure of perceived cognitive impairment. The group mean rose from 29.1 to 55.5. The design cannot establish that oxaloacetate caused the change.

Was oxaloacetate tested against a placebo?

No. The reported study had no control group. A randomized, placebo-controlled phase II study is expected to begin enrolling before the end of 2026.

What side effects were reported?

The treatment was described as generally well tolerated, with gastrointestinal symptoms including indigestion, bloating, constipation and diarrhea. The supplied report does not give detailed rates or long-term safety findings.

Does the study mean oxaloacetate is a proven treatment for brain fog?

No. These are preliminary findings from a small study. Larger controlled research is needed to test whether the supplement itself improves symptoms and to assess how safe and durable any benefit may be.

Source: rss

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Coffee Doesn’t Have To Keep You Awake To Disrupt Your Sleep

Emerging research suggests coffee may interfere with sleep even if it doesn’t cause alertness, raising questions about consumption timing and effects.

After Positive Fecal Test, Here’s What Gets Patients To Colonoscopy

A meta-analysis found navigation and reminders improved follow-up colonoscopy after positive stool tests, but completion remained below the 80% target.

Popular Longevity Supplement Fails To Meet Endpoint In Parkinson’s Trial

A 410-person phase III trial found no clinical benefit from nicotinamide riboside in early Parkinson’s disease, despite raising blood NAD levels.

Molina Healthcare Surges In Global Coverage

Molina Healthcare experiences a surge in international coverage, marking a major expansion in its global presence, confirmed by recent data.